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ABSTRACT
Objective: There is an increasing use of colistin consequent to increase in the infections caused by carbapenem-resistant Klebsiella pneumoniae. 
The present study was conducted to determine the minimum inhibitory concentration (MIC) of colistin and the resistance pattern of colistin in 
carbapenem-resistant K. pneumoniae (CRKP) strains in our intensive care unit (ICU).
Methods: Antibiotic susceptibility testing for other antimicrobial agents was done by Kirby-Bauer disk diffusion method. MIC of colistin was 
determined by agar dilution method. The results of antibiotic susceptibility testing were interpreted as per Clinical Laboratory Standard Institute 
guidelines 2016 and MIC of colistin were interpreted as per European Committee on Antimicrobial susceptibility testing. The carbapenem resistance 
was phenotypically detected by modified hodge test and imipenem/imipenem ethylenediaminetetraacetic acid disk method.
Results: Out of 518 K. pneumoniae, 329 were resistant to carbapenems, and 91 isolates showed resistance to colistin. The MIC of colistin ranged 
between 4 and >512 ug/ml and MIC90 was 16 ug/L and MIC50 was 4 ug/ml. A majority of the colistin-resistant isolates were found in multidisciplinary 
ICU (85/91).
Conclusion: The emergence of colistin-resistant strains is a major problem due to limited treatment options for infections caused by CRKP 
carbapenemase producing K. pneumoniae. Colistin should not be used alone, combination therapy should be preferred.
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INTRODUCTION
Enterobacteriaceae are one of the major agents of hospital and 
community-acquired infections; these cause increased morbidity and 
mortality, especially with increased resistance rates [1]. Extended 
spectrum betalactamases (ESBLs) lead to multidrug resistance by 
transfer between bacteria and are seen in Enterobacteriaceae [2]. 
Carbapenems are important group of antibiotics used as a 
last option, especially in ESBL producing multi-drug resistant 
Enterobacteriaceae [3]. As a result of increased use of carbapenems, 
carbapenemases are widespread in Enterobacteriaceae family and 
particularly in Klebsiella pneumoniae; so effective treatment options are 
decreasing [2,4]. Carbapenemase-producing K. pneumoniae emerged in 
the late 1990s and has become a serious health problem worldwide [5].
Carbapenem-resistant K. pneumoniae (CRKP) can cause nosocomial 
infections and outbreaks with high mortality rates. Such infections 
occur mainly in patients admitted to intensive care units (ICU) with 
several underlying diseases and histories of having received prolonged 
courses of antibiotics [6]. Several resistance mechanisms have been 
described. Carbapenemase production (K. pneumoniae carbapenemase 
[KPC]), metallo-β-lactamase (MBL) and porin loss, combined with 
the overproduction of ESBL, are described as the most common 
mechanisms of carbapenem resistance [7,8].
Carbapenemases producing K. pneumoniae strains are considered 
endemic in some areas. For example, studies by the European 
Antimicrobial Resistance Surveillance (EARS-net) showed that the 
prevalence of carbapenem-resistant K. pneumoniae has increased from 
1-2% to 15% in Italy in 2006-2009 [9]. Due to this resistance spreading 
rapidly around the world, there has been a need for new therapeutic 
agents. Polymyxin and colistin were out of use since the early 1970s due 
to its side effects of neurotoxicity and nephrotoxicity, but colistin has 
become a preferred antimicrobial agent with increase of infections with 
resistant Enterobacteriaceae [10-12]. However, excessive use of colistin 
has led to resistance to this drug [13]. The resistance to colistin seen 
in K. pneumoniae strains is reported to be due to reduced affinity of 
colistin to lipopolysaccharide target [5]. In this study, colistin resistance 
in CRKP strains has been identified and evaluated.
Since there are not many studies with determination of colistin 
minimum inhibitory concentration (MIC), we undertook this study to 
estimate and evaluate colistin resistance in our hospital by MIC.
MATERIALS AND METHODS
The present study was carried out in a Tertiary Care Hospital of 
Karnataka, South India, with bed strength of 650. A total of 518 non-
repetitive clinical isolates of K. pneumoniae were collected over a 
period of 3 years (2014-2016) from our ICUs, i.e. multidisciplinary 
ICU (MICU), neurosurgery ICU, intensive thoracic unit, neonatal ICU, 
pediatric ICU, coronary care unit, and renal ICU. These isolates were 
obtained from endotracheal aspirate (111), blood (80), urine (59), pus 
(22), bronchoalveolar lavage and sputum (21), catheter tips (15), fluids 
(13), and tissue specimens (8).
K. pneumoniae was identified using standard biochemical methods
Disk-diffusion tests were performed to determine susceptibility to 
antimicrobials, according to the Clinical and Laboratory Standards 
Institute (CLSI). Escherichia coli ATCC 25922 was used as a quality 
control. Isolates were screened for the ESBL phenotype by the standard 
double-disk synergy test, and KPC was screened both by evaluating 
breakpoints and using modified Hodge test, according to CLSI 
guidelines [14].
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Imipenem plus ethylenediaminetetraacetic acid (EDTA) discs were used 
to detect the presence of MBL (HiMedia Laboratories, Mumbai). MICs of 
meropenem and colistin (Sigma-Aldrich Corporation, St. Louis, US) were 
determined by the agar dilution method according to the guidelines from 
the CLSI [14]. The colistin breakpoint was evaluated using breakpoints 
for Enterobacteriaceae recommended by the European Committee 
on Antibiotic Susceptibility Testing. (resistant: >2 ug/ml; sensitive: 
≤2 ug/ml). K. pneumoniae ATCC 700603 was used as a quality control.
RESULTS
Totally 518 isolates of K. pneumoniae were isolated during the study, 
of which 329 (63.5%) isolates were CRKP isolates. The clinical source 
and distribution of K. pneumoniae in different ICUs are shown in 
Tables 1 and 2.
The antibiotic susceptibility of CRKP to other drugs is shown in Table 3. 
Antibiotic susceptibility testing revealed that very few antibiotics were 
susceptible.
With regard to colistin 91/329 (27.65%), isolates were resistant and 
the MIC ranged between 4 and >512 ug/ml. MIC90 and MIC50 of colistin 
were 16 and 4 ug/ml (Fig. 1).
In the present study, we found that 85/91 (93.4%) isolates that showed 
resistance to colistin were from MICU and resistance to carbapenems 
also seen in MICU (83.3%).
Out of 329 carbapenem-resistant isolates, 216 were positive for 
modified-Hodge test and 59 K. pneumoniae were screened positive 
for imipenem/imipennem EDTA test. The rest of the 54 carbapenem-
resistant isolates were negative for both tests.
DISCUSSION
K. pneumoniae is highly prevalent in hospitals and causes many 
nosocomial infections. The emergence of drug resistance in K. 
pneumoniae continues to be of critical concern for the choice of 
treatment options against infections caused by this bacterium.
Carbapenem resistance in Klebsiella spp. is an emerging problem and is 
a cause of concern as many nosocomial Klebsiella spp. are detected to be 
resistant to most other antibiotics.
Colistin is used as last resort of antimicrobials, especially in the 
present worrisome therapeutic scenario of multidrug resistant 
and pan drug-resistant Gram-negative infections. The drug acts on 
outer cell membrane of Gram-negative bacteria (GNB) and releases 
lipopolysaccharides [15]. This in turn results into disruption of cell 
membrane leading to leakage of cell content, causing cell lysis and 
finally cell death [16,17]. Within years after the reuse of colistin, there 
have been reports of colistin-resistant strains [18]. Indiscriminate 
antibiotic use in India is leading to cases of bacteria resistant to colistin.
ICUs are the epicenter for spawning multidrug resistance within 
hospitals. Many patients are transferred to the ICU from other 
healthcare facilities, where they have acquired resistant pathogens. 
Patients within the ICU undergo invasive procedures, treatment with 
antibiotic.
Combinations and exposure to other patients with resistant 
pathogens [19]. Multiple mechanisms exist for ICU pathogens to acquire 
antibiotic resistance. These mechanisms include enzymatic inhibition 
of drugs, alteration of proteins targeted by antibiotics, changes in 
metabolic pathways, antibiotic efflux, alterations in porin channels, and 
changes of membrane permeability [20].
In the present study, we found 63.5% (329/518) K. pneumoniae was 
multidrug resistant. The majority of the carbapenem resistant isolates 
were isolated form tracheal aspirate (33.73%), followed by blood 
(24.3%) and urine (17.9%). Gupta et al. found resistance to meropenem 
(22.16%) was more compared to imipenem (17.32%) in his study from 
different bacteria.
He also found that a significantly high resistance was seen in ICU patients, 
37.3% and 31.9% for meropenem and imipenem, respectively [21]. 
El-Mahdy et al. in his work on cancer patients found only 4% of them 
were resistant to carbapenems [22]. Bashir et al. in his research study 
found 27.9% isolates were carbapenem-resistant [23].
Dizbay et al. [24] analyzed nosocomial infections produced by 
carbapenem-resistant Klebsiella spp. in ICU and their risk factors. They 
found that carbapenem resistance is significantly high in ICUs and more 
Table 1: Clinical sources of carbapenem‑resistant Klebsiella 
pneumoniae (329)
Clinical specimen N (%)




BAL and sputum 21 (6.4)
Catheter tips 15 (4.5)
Fluids 13 (3.95)
Tissue 8 (2.4)









ICU: Intensive care unit, MICU: Multidisciplinary intensive care unit, 
NSICU: Neurosurgery intensive care unit, ITU: Intensive thoracic unit, 
NICU: Neonatal intensive care unit, PICU: Pediatric intensive care unit, CCU: 
Critical care unit, RICU: Renal intensive care unit, CRKP: Carbapenem-resistant 
K. pneumoniae
Table 3: Antibiotic susceptibility pattern of CRKP* (n=329)






Ciprofloxacin  9 (2.7)
Ofloxacin 10 (3.0)
Levofloxacin 22 (6.6)
*All cephalosporins, betalacatamase, and betalactamase inhibitors were 
resistant. CRKP: Carbapenem-resistant Klebsiella pneumoniae
Fig. 1: Minimum inhibitory concentration (MIC) of colistin. 
MIC90 – 16 ug/ml and MIC50 – 4 ug/ml
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frequent (78.57%), and resistance was more often seen in respiratory 
tract specimens.
In the current study, all the isolates were screened for MIC of colistin. 
The prevalence of colistin resistance in K. pneumoniae from ICUs was 
(91/329) 27.65%, and the MIC ranged between 4 and >512 ug/ml.
Taneja et al. in a study from North India found 16% of the carbapenem-
resistant strains were resistant to both tigecycline and colistin [25]. 
Giani et al. in Italy conducted a nationwide cross-sectional survey 
on CRE, carried out in mid-2011, the overall percentage of colistin 
resistance among KPC-KP was found to be 22.4% [26]. In another study 
in Italy Capone et al. observed 36.1% resistance to colistin in CRKP [18]. 
In a recent study by Kontopidou et al., 51 (34%) patients were colonized 
by pathogens with an intrinsic resistance to colistin [13].
Ghafur et al. reported a series of 13 patients with colistin resistance 
from South India [27].
With the increased emergence and spread of CRKP, treatment options 
are dcecreasing. As a reserve agent, colistin has been the drug of choice 
in the treatment of CRKP, but with the rise of carbapenem resistance, 
the colistin usage has been increased over the years leading to slow 
emergence of colistin resistance. Especially, if these antibiotics are not 
used in combinations, they are not enough as therapeutic agent’s leads 
to treatment failure and high mortality rates. The high rate of resistance 
to colistin and carbapenems is worrisome, but the MIC of colistin and 
carbapenems helps the clinician to choose the drug in appropriate 
combinations.
Shah et al. conducted a study in a tertiary care hospital in Mumbai, the 
purpose of this study was to evaluate the efficacy of colistin-carbapenem 
combination against Carbapenem-resistant GNB (CRGNB) infection in a 
clinical study and an in vitro synergy study using Etest. Overall, 60.6% 
clinical success was observed in patients receiving colistin-carbapenem 
combination against CRGNB infection [28].
Tumbarello et al. [29] in his study emphasized the importance 
of combination therapy in carbapenemase-producing Klebsiella 
pneumonia. Combination therapy with tigecycline, colistin, and 
meropenem (MIC upto 8 ug/ml) was associated with lower mortality.
In another study by Daikos et al. [30] stated that combination therapy 
with carbapenem MIC of 8 was more beneficiary in severely ill patients 
by lowering the mortality rate.
CONCLUSION
The present study showed the emergence of colistin resistance among 
clinical isolates of K. pneumoniae which are alarming in ICUs. It is 
important to determine the MIC of colistin to formulate an effective 
treatment protocol, even for the resistant isolates. For the resistant 
cases, colistin should be used in combination with other antimicrobials 
for therapy. Necessary infection control precautions and increased 
awareness to prevent further rise in the drug resistance against this 
last resort of antimicrobials is important. A restricted and rational use 
of the colistin is the need of hour.
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